Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Elaine Soliven, 24 Feb 2020
Administering intravenous propranolol hydrochloride does not reduce the duration of labour induction for nulliparous women who undergo vaginal delivery, according to a study presented at SMFM 2020.

MuGard, Caphosol no better than standard therapy for chemo-induced oral mucositis

04 May 2020

MuGard and Caphosol do not appear to be more effective than standard topical therapy at reducing pain scores or increasing mucosal recovery in the treatment of chemotherapy-induced oral mucositis, a recent study has shown.

This study was conducted to address the limited data available regarding the treatment of established oral mucositis with oral mucoadhesive hydrogel (MuGard) or supersaturated calcium phosphate oral rinse (Caphosol) compared to standard therapies.

The authors performed a retrospective chart review involving adults treated with MuGard, Caphosol and/or standard topical therapy for established oral mucositis while admitted to a community teaching hospital. Then, they matched patients receiving newer agents (MuGard/Caphosol) to those receiving standard topical therapy (ST) using a posthoc propensity score.

Of the 147 patients included in the analysis, 14 from each group were matched. No difference in the primary endpoint of median change in average daily pain score, compared to baseline, was found between matched groups at day 3 (ST vs MuGard/Caphosol: 0 vs 0.18; p=0.830) or day 7 (0 vs 0.8; p=0.494).

There were also no between-group differences seen in opioid usage, oral mucositis symptom duration or progression, or incidence of documented infection.

“Oral mucositis, a common complication of several different anticancer therapies, causes significant morbidity in cancer patients,” the authors said. “It is characterized by the destruction of the mucosa throughout the gastrointestinal tract including the oral cavity.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Elaine Soliven, 24 Feb 2020
Administering intravenous propranolol hydrochloride does not reduce the duration of labour induction for nulliparous women who undergo vaginal delivery, according to a study presented at SMFM 2020.